SIGA Technologies, Inc. — FY2013 Form 10-K
Reporting period: Year ended December 31, 2013; the filing also reports fourth-quarter results. Filed March 10, 2014.
Business context
SIGA develops treatments for unmet medical needs and biothreats. Its lead product, Arestvyr (tecovirimat/ST-246), is an investigational orthopoxvirus antiviral—not FDA-approved for any indication—and is being supplied to the U.S. Strategic National Stockpile under a BARDA contract. The amended contract calls for BARDA to purchase 1.7 million courses; SIGA is also to provide 300,000 courses at no cost. SIGA is pursuing Arestvyr development and has earlier-stage dengue and arenavirus candidates.
Financial performance and position
| Metric | FY2013 | FY2012 |
|---|---|---|
| Revenue | $5.5 million | $9.0 million |
| Operating loss | $23.5 million | $22.5 million |
| Net loss | $17.2 million | $14.1 million |
| Operating cash flow | $58.4 million provided | $20.2 million used |
| Cash and cash equivalents at year-end | $91.3 million | $32.0 million |
- Revenue fell 39%, primarily from lower federal contract and grant activity. SG&A increased 16% to $13.2 million; R&D declined 24% to $13.9 million. Restructuring charges were $0.5 million.
- FY2013 included a $7.6 million income-tax benefit. SIGA remained loss-making at the operating level; reported revenue does not reflect most BARDA product deliveries because related revenue is deferred.
- BARDA paid approximately $109.7 million in 2013: $96.1 million for delivery of about 725,000 paid courses, $5.4 million for R&D/support, and an $8.2 million milestone. SIGA also delivered 195,000 courses at no cost. At year-end, deferred revenue was $162.2 million and deferred costs were $22.6 million.
- Current assets were $123.9 million and current liabilities $12.2 million (about 10.2 times current-asset coverage). Total assets were $193.8 million; total liabilities $176.8 million. Year-end debt was approximately $4.0 million, bearing 9.85% fixed interest; no revolving credit was available because there were no eligible receivables.
- Fourth-quarter 2013 revenue was $0.9 million, operating loss $6.5 million, and net loss $4.3 million, versus $2.5 million, $5.3 million, and $2.6 million, respectively, in Q4 2012.
Changes, outlook, and material risks
- In Q4, SIGA began an Optimization Program that included staff reductions and curtailment of early-stage discovery work. Management targeted $6 million in annual operating-expense savings, with a substantial portion implemented by year-end.
- Management said cash, BARDA receipts, and continuing government contracts and grants should fund operations beyond the next 12 months. This assessment is exposed to delivery timing, government funding decisions, and the PharmAthene litigation. No earnings or revenue guidance was provided.
- In February 2014, SIGA reported delivery of approximately 256,000 courses accepted into the stockpile; about 192,000 were expected to be invoiced for $25.4 million, with the balance supplied at no cost.
- PharmAthene litigation remains a major contingency. Delaware’s Supreme Court upheld SIGA’s breach of its obligation to negotiate in good faith, reversed prior damages and promissory-estoppel findings, and remanded for consideration of possible expectation damages and fees. SIGA recorded a $2.6 million contingency for fees, expenses, and interest; potential damages remain unclear.
- Government contracts and grants are concentrated sources of revenue and may be modified, canceled, or not renewed. Arestvyr faces regulatory, animal-efficacy, manufacturing, and commercialization risks; it relies on third-party manufacturers and the FDA animal-rule pathway.
- Revenue recognition is unusually significant: BARDA product receipts and deliveries are generally deferred because of replacement obligations. Future recognition depends on satisfying contractual obligations, and the filing warns some deferred amounts may not ultimately be recognized.
- Management reported effective disclosure controls and internal control over financial reporting at December 31, 2013; the auditor also gave an unqualified opinion. A material weakness identified in 2012 related to warrant anti-dilution accounting was reported as remediated.
Investor verification priorities
- Track BARDA acceptance, invoicing, cash collections, deferred-revenue recognition, and the costs attached to delivered courses.
- Review the PharmAthene remand outcome and potential damages, fees, and effects on retained BARDA profits and deferred-tax-asset assumptions.
- Assess whether the $6 million expense-reduction target is achieved and how reduced discovery spending affects funded programs and grants.
- Confirm progress toward Arestvyr regulatory approval, efficacy evidence, manufacturing readiness, and any additional BARDA options or government funding.
- Monitor liquidity and debt service alongside government-contract dependence; distinguish cash inflows from revenue and operating profitability.